Gene therapy company Genprex Inc (NASDAQ:GNPX) reported on Tuesday the receipt of US Food and Drug Administration (FDA) Fast Track Designation for its Oncoprex immunogene therapy in combination with osimertinib for non-small cell lung cancer (NSCLC).
The Oncoprex immunogene therapy in combination with AstraZeneca's EGFR inhibitor osimertinib is being studied for the treatment of non-small cell lung cancer (NSCLC) patients with EFGR mutations that progressed after treatment with osimertinib alone.
Oncoprex is comprised of the TUSC2 (Tumor Suppressor Candidate 2) gene complexed with a lipid nanoparticle. TUSC2 is the active agent in Oncoprex, added the company.
In conjunction, the company said it has treated more than 50 lung cancer patients with Oncoprex in Phase I and II clinical trials. The data from these trials are encouraging as to both safety and efficacy. The initial disease indication for Oncoprex is NSCLC.
According to the company, it is preparing to initiate a Phase I/II clinical trial evaluating Oncoprex in combination with osimertinib, as well as a new Phase I clinical trial evaluating Oncoprex in combination with a checkpoint inhibitor.
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study